nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

07.07.2023 | Original Article

Association of serum uric acid levels with bone mineral density and the presence of osteoporosis in Chinese patients with Parkinson’s disease: a cross-sectional study

verfasst von: Cong Ma, Ronghui Yu, Junhong Li, Xiaoyan Wang, Jingjing Guo, Erya Xiao, Ping Liu

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

As the population ages, the incidence of osteoporosis among patients suffering from Parkinson's disease (PD) will surge continually, and the ensuing disability from falls is becoming a serious social burden. Due to its antioxidant properties, much literature has indicated the possible ability of serum uric acid (UA) to prevent ageing-related diseases caused by oxidative stress, including osteoporosis and PD. Therefore, this study was for exploring the connection of serum UA levels with bone mineral density (BMD) and the osteoporosis presence in Chinese PD patients.

Materials and methods

A cross-sectional design was used to statistically analyze 42 clinical parameters obtained from 135 patients with PD treated in Wuhan Tongji Hospital during 2020–2022. Multiple stepwise linear regression and multiple logistic regression analyses were constructed for identifying the association of serum UA levels with BMD as well as osteoporosis in PD patients, respectively. With receiver operative characteristic (ROC) curves, the optimal cutoff value was acquired for serum UA in the diagnosis of osteoporosis.

Results

According to the regression analysis adjusted for confounders, serum UA levels in PD patients had positive correlation with BMD at each site and negative correlation with the presence of osteoporosis (P < 0.05 for all). ROC curves determined that the optimal cutoff value for UA to perform well in diagnosing osteoporosis in PD patients was 284.27 μmol/L (P < 0.001).

Conclusion

Relatively higher serum UA levels in the physiological range can work as a biomarker of higher BMD, and were strongly linked to lower prevalence of osteoporosis in Chinese PD patients.

Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS et al (2019) Parkinson’s disease in the Western Pacific Region. Lancet Neurol 18:865–879. https://doi.org/10.1016/S1474-4422(19)30195-4CrossRefPubMed

Abou-Raya S, Helmii M, Abou-Raya A (2009) Bone and mineral metabolism in older adults with Parkinson’s disease. Age Ageing 38:675–680. https://doi.org/10.1093/ageing/afp137CrossRefPubMed

Lee A, Gilbert RM (2016) Epidemiology of Parkinson disease. Neurol Clin 34:955–965. https://doi.org/10.1016/j.ncl.2016.06.012CrossRefPubMed

Tan AH, Hew YC, Lim SY, Ramli NM, Kamaruzzaman SB et al (2018) Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson’s disease. Parkinsonism Relat Disord 56:58–64. https://doi.org/10.1016/j.parkreldis.2018.06.020CrossRefPubMed

van den Bos F, Speelman AD, Samson M, Munneke M, Bloem BR, Verhaar HJ (2013) Parkinson’s disease and osteoporosis. Age Ageing 42:156–162. https://doi.org/10.1093/ageing/afs161CrossRefPubMed

Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R, Lees AJ (2014) Bone health in Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 85:1159–1166. https://doi.org/10.1136/jnnp-2013-307307CrossRefPubMed

Ensrud KE, Crandall CJ (2017) Osteoporosis. Ann Internal Med 167:ITC17–ITC32. https://doi.org/10.7326/AITC201708010CrossRef

Choi SM, Cho SH, Kim BC (2021) Association between freezing of gait and bone mineral density in patients with Parkinson’s disease. Neurol Sci 42:2921–2925. https://doi.org/10.1007/s10072-020-04920-6CrossRefPubMed

Muhlenfeld N, Sohling N, Marzi I, Pieper M, Paule E et al (2021) Fractures in Parkinson’s Disease: injury patterns, hospitalization, and therapeutic aspects. Eur J Trauma Emerg Surg 47:573–580. https://doi.org/10.1007/s00068-019-01240-zCrossRefPubMed

10.

Sleeman I, Che ZC, Counsell C (2016) Risk of fracture amongst patients with Parkinson’s disease and other forms of parkinsonism. Parkinsonism Relat Disord 29:60–65. https://doi.org/10.1016/j.parkreldis.2016.05.026CrossRefPubMed

11.

Shribman S, Torsney KM, Noyce AJ, Giovannoni G, Fearnley J, Dobson R (2014) A service development study of the assessment and management of fracture risk in Parkinson’s disease. J Neurol 261:1153–1159. https://doi.org/10.1007/s00415-014-7333-8CrossRefPubMedCentralPubMed

12.

Kimball JS, Johnson JP, Carlson DA (2021) Oxidative stress and osteoporosis. J Bone Joint Surg Am 103:1451–1461. https://doi.org/10.2106/JBJS.20.00989CrossRefPubMed

13.

Subramaniam SR, Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol 106–107:17–32. https://doi.org/10.1016/j.pneurobio.2013.04.004CrossRefPubMed

14.

Wei W, Ji S (2018) Cellular senescence: molecular mechanisms and pathogenicity. J Cell Physiol 233:9121–9135. https://doi.org/10.1002/jcp.26956CrossRef

15.

El Assar M, Angulo J, Rodriguez-Manas L (2013) Oxidative stress and vascular inflammation in aging. Free Radical Biol Med 65:380–401. https://doi.org/10.1016/j.freeradbiomed.2013.07.003CrossRef

16.

El Ridi R, Tallima H (2017) Physiological functions and pathogenic potential of uric acid: a review. J Adv Res 8:487–493. https://doi.org/10.1016/j.jare.2017.03.003CrossRefPubMedCentralPubMed

17.

Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA (2005) Uric acid and oxidative stress. Curr Pharm Des 11:4145–4151. https://doi.org/10.2174/138161205774913255CrossRefPubMed

18.

Veronese N, Carraro S, Bano G, Trevisan C, Solmi M et al (2016) Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis. Eur J Clin Invest 46:920–930. https://doi.org/10.1111/eci.12677CrossRef

19.

Sampat R, Young S, Rosen A, Bernhard D, Millington D et al (2016) Potential mechanisms for low uric acid in Parkinson disease. J Neural Transm (Vienna) 123:365–370. https://doi.org/10.1007/s00702-015-1503-4CrossRefPubMed

20.

Yan DD, Wang J, Hou XH, Bao YQ, Zhang ZL et al (2018) Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population. Acta Pharmacol Sin 39:626–632. https://doi.org/10.1038/aps.2017.165CrossRefPubMed

21.

Iki M, Yura A, Fujita Y, Kouda K, Tachiki T et al (2020) Relationships between serum uric acid concentrations, uric acid lowering medications, and vertebral fracture in community-dwelling elderly Japanese men: Fujiwara-kyo osteoporosis risk in men (FORMEN) cohort study. Bone 139:115519. https://doi.org/10.1016/j.bone.2020.115519CrossRefPubMed

22.

Ahn SH, Lee SH, Kim BJ, Lim KH, Bae SJ et al (2013) Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int 24:2961–2970. https://doi.org/10.1007/s00198-013-2377-7CrossRefPubMed

23.

Kaushal N, Vohora D, Jalali RK, Jha S (2018) Raised serum uric acid is associated with higher bone mineral density in a cross-sectional study of a healthy Indian population. Ther Clin Risk Manag 14:75–82. https://doi.org/10.2147/TCRM.S147696CrossRefPubMedCentralPubMed

24.

Ibrahim WN, Younes N, Shi Z, Abu-Madi MA (2021) Serum uric acid level is positively associated with higher bone mineral density at multiple skeletal sites among healthy qataris. Frontiers Endocrinol 12:653685. https://doi.org/10.3389/fendo.2021.653685CrossRef

25.

Karimi F, Dabbaghmanesh MH, Omrani GR (2019) Association between serum uric acid and bone health in adolescents. Osteoporos Int 30:2057–2064. https://doi.org/10.1007/s00198-019-05072-wCrossRefPubMed

26.

Li X, Li L, Yang L, Yang J, Lu H (2021) No association between serum uric acid and lumbar spine bone mineral density in US adult males: a cross sectional study. Sci Rep 11:15588. https://doi.org/10.1038/s41598-021-95207-zCrossRefPubMedCentralPubMed

27.

Zhang D, Bobulescu IA, Maalouf NM, Adams-Huet B, Poindexter J et al (2015) Relationship between serum uric acid and bone mineral density in the general population and in rats with experimental hyperuricemia. J Bone Miner Res 30:992–999. https://doi.org/10.1002/jbmr.2430CrossRefPubMed

28.

Afsar B, Sag AA, Oztosun C, Kuwabara M, Cozzolino M et al (2019) The role of uric acid in mineral bone disorders in chronic kidney disease. J Nephrol 32:709–717. https://doi.org/10.1007/s40620-019-00615-0CrossRefPubMed

29.

Yan P, Zhang Z, Wan Q, Zhu J, Li H et al (2018) Association of serum uric acid with bone mineral density and clinical fractures in Chinese type 2 diabetes mellitus patients: a cross-sectional study. Clinica Chimica Acta Int J Clin Chem 486:76–85. https://doi.org/10.1016/j.cca.2018.07.033CrossRef

30.

Wang J, Xie P, Huang JM, Qu Y, Zhang F et al (2016) The new Asian modified CKD-EPI equation leads to more accurate GFR estimation in Chinese patients with CKD. Int Urol Nephrol 48:2077–2081. https://doi.org/10.1007/s11255-016-1386-9CrossRef

31.

Delanaye P, Masson I, Maillard N, Pottel H, Mariat C (2022) The new 2021 CKD-EPI equation without race in a european cohort of renal transplanted patients. Transplantation 106:2443–2447. https://doi.org/10.1097/TP.0000000000004234CrossRefPubMed

32.

Zhao X, Yu X, Zhang X (2020) Association between uric acid and bone mineral density in postmenopausal women with type 2 diabetes mellitus in china: a cross-sectional inpatient study. J Diabetes Res 2020:3982831. https://doi.org/10.1155/2020/3982831CrossRefPubMedCentralPubMed

33.

Zhao DD, Jiao PL, Yu JJ, Wang XJ, Zhao L et al (2016) Higher serum uric acid is associated with higher bone mineral density in chinese men with type 2 diabetes mellitus. Int J Endocrinol 2016:2528956. https://doi.org/10.1155/2016/2528956CrossRefPubMedCentralPubMed

34.

Xu M, Su J, Hao J, Zhong N, Zhang Z et al (2018) Positive association between serum uric acid and bone mineral density in Chinese type 2 diabetes mellitus stratified by gender and BMI. J Bone Miner Metab 36:609–619. https://doi.org/10.1007/s00774-017-0877-9CrossRefPubMed

35.

Lin ZC, Wu JF, Chang CY, Lai KM, Yang HY (2022) Association between serum uric acid level and bone mineral density at multiple skeletal sites in middle-aged and elderly men: a cross-sectional study of a healthy population in Taiwan. Arch Osteoporos 17:142. https://doi.org/10.1007/s11657-022-01186-7CrossRefPubMed

36.

Xiao J, Chen W, Feng X, Liu W, Zhang Z et al (2017) Serum uric acid is associated with lumbar spine bone mineral density in healthy Chinese males older than 50 years. Clin Interv Aging 12:445–452. https://doi.org/10.2147/CIA.S130690CrossRefPubMedCentralPubMed

37.

Chen F, Wang Y, Guo Y, Wang J, Yang A et al (2019) Specific higher levels of serum uric acid might have a protective effect on bone mineral density within a Chinese population over 60 years old: a cross-sectional study from northeast China. Clin Interv Aging 14:1065–1073. https://doi.org/10.2147/CIA.S186500CrossRefPubMedCentralPubMed

38.

Pan K, Yao X, Liu M, Zhu Z (2020) Association of serum uric acid status with bone mineral density in adolescents aged 12–19 years. Front Med (Lausanne) 7:255. https://doi.org/10.3389/fmed.2020.00255CrossRefPubMed

39.

Hohn A, Tramutola A, Cascella R (2020) Proteostasis failure in neurodegenerative diseases: focus on oxidative stress. Oxid Med Cell Longev 2020:5497046. https://doi.org/10.1155/2020/5497046CrossRefPubMedCentralPubMed

40.

Seifar F, Dinasarapu AR, Jinnah HA (2022) Uric acid in Parkinson’s disease: what is the connection? Mov Disord 37:2173–2183. https://doi.org/10.1002/mds.29209CrossRefPubMed

41.

Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jimenez-Urbieta H, Rodriguez-Oroz MC (2016) Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov Disord 31:861–881. https://doi.org/10.1002/mds.26662CrossRefPubMed

42.

van Wamelen DJ, Taddei RN, Calvano A, Titova N, Leta V et al (2020) Serum uric acid levels and non-motor symptoms in Parkinson’s disease. J Parkinsons Dis 10:1003–1010. https://doi.org/10.3233/JPD-201988CrossRefPubMed

43.

Callaway DA, Jiang JX (2015) Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab 33:359–370. https://doi.org/10.1007/s00774-015-0656-4CrossRefPubMed

44.

Rao AV, Balachandran B (2002) Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 5:291–309. https://doi.org/10.1080/1028415021000033767CrossRefPubMed

45.

Li HZ, Chen Z, Hou CL, Tang YX, Wang F, Fu QG (2015) Uric acid promotes osteogenic differentiation and inhibits adipogenic differentiation of human bone mesenchymal stem cells. J Biochem Mol Toxicol 29:382–387. https://doi.org/10.1002/jbt.21707CrossRefPubMed

46.

Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR (1990) Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Investig 85:632–639. https://doi.org/10.1172/JCI114485CrossRefPubMedCentralPubMed

47.

Steinbeck MJ, Appel WH Jr, Verhoeven AJ, Karnovsky MJ (1994) NADPH-oxidase expression and in situ production of superoxide by osteoclasts actively resorbing bone. J Cell Biol 126:765–772. https://doi.org/10.1083/jcb.126.3.765CrossRefPubMed

48.

Lin KM, Lu CL, Hung KC, Wu PC, Pan CF et al (2019) The paradoxical role of uric acid in osteoporosis. Nutrients. https://doi.org/10.3390/nu11092111CrossRefPubMedCentralPubMed

49.

Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G (2008) The paradoxical relationship between serum uric acid and cardiovascular disease. Clinica Chimica Acta Int J Clin Chem 392:1–7. https://doi.org/10.1016/j.cca.2008.02.024CrossRef

50.

Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G (1999) When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 340:143–152CrossRefPubMedCentralPubMed

51.

Sautin YY, Johnson RJ (2008) Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27:608–619. https://doi.org/10.1080/15257770802138558CrossRefPubMedCentralPubMed

52.

Ishii S, Miyao M, Mizuno Y, Tanaka-Ishikawa M, Akishita M, Ouchi Y (2014) Association between serum uric acid and lumbar spine bone mineral density in peri- and postmenopausal Japanese women. Osteoporos Int 25:1099–1105. https://doi.org/10.1007/s00198-013-2571-7CrossRefPubMed

53.

Makovey J, Macara M, Chen JS, Hayward CS, March L et al (2013) Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone 52:400–406. https://doi.org/10.1016/j.bone.2012.10.025CrossRefPubMed

54.

Pirro M, Mannarino MR, Bianconi V, De Vuono S, Sahebkar A et al (2017) Uric acid and bone mineral density in postmenopausal osteoporotic women: the link lies within the fat. Osteoporos Int 28:973–981. https://doi.org/10.1007/s00198-016-3792-3CrossRefPubMed

55.

Tamba S, Nishizawa H, Funahashi T, Okauchi Y, Ogawa T et al (2008) Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med 47:1175–1180. https://doi.org/10.2169/internalmedicine.47.0603CrossRef

56.

Tsushima Y, Nishizawa H, Tochino Y, Nakatsuji H, Sekimoto R et al (2013) Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem 288:27138–27149. https://doi.org/10.1074/jbc.M113.485094CrossRefPubMedCentralPubMed

57.

Chen W, Roncal-Jimenez C, Lanaspa M, Gerard S, Chonchol M et al (2014) Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism 63:150–160. https://doi.org/10.1016/j.metabol.2013.09.018CrossRefPubMed

58.

Fujita Y, Iki M, Tamaki J, Kouda K, Yura A et al (2013) Renal function and bone mineral density in community-dwelling elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) study. Bone 56:61–66. https://doi.org/10.1016/j.bone.2013.05.004CrossRefPubMed

Titel: Association of serum uric acid levels with bone mineral density and the presence of osteoporosis in Chinese patients with Parkinson’s disease: a cross-sectional study
verfasst von: Cong Ma
Ronghui Yu
Junhong Li
Xiaoyan Wang
Jingjing Guo
Erya Xiao
Ping Liu
Publikationsdatum: 07.07.2023
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 5/2023
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-023-01446-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Association of serum uric acid levels with bone mineral density and the presence of osteoporosis in Chinese patients with Parkinson’s disease: a cross-sectional study

Abstract

Introduction

Materials and methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Heel bone mineral density and various oral diseases: a bidirectional Mendelian randomization

Soft drinks, tea and coffee consumption in relation to risk of fracture: evidence from china health and nutrition survey

Evaluation of the trabecular bone score in 35 children and adults with X-linked hypophosphatemic rickets

JSBMR and JBMM mourn the death of Dr. Fujio Suzuki

Low-intensity pulsed ultrasound enhances the positive effects of high-intensity treadmill exercise on bone in rats

Untreated osteoporosis and higher FRAX as risk factors for tooth loss: a 5-year prospective study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin